218 related articles for article (PubMed ID: 15783246)
21. Transient efficacy of octreotide and pasireotide (SOM230) treatment in GIP-dependent Cushing's syndrome.
Preumont V; Mermejo LM; Damoiseaux P; Lacroix A; Maiter D
Horm Metab Res; 2011 Apr; 43(4):287-91. PubMed ID: 21264796
[TBL] [Abstract][Full Text] [Related]
22. [Cushing syndromes due to aberrant expression of functional receptors other than ACTH. A new organic hypercorticism syndrome entity].
Ancion G; Hennen G
Rev Med Liege; 2000 Oct; 55(10):929-34. PubMed ID: 11244801
[TBL] [Abstract][Full Text] [Related]
23. Asynchronous development of bilateral nodular adrenal hyperplasia in gastric inhibitory polypeptide-dependent cushing's syndrome.
N'Diaye N; Hamet P; Tremblay J; Boutin JM; Gaboury L; Lacroix A
J Clin Endocrinol Metab; 1999 Aug; 84(8):2616-22. PubMed ID: 10443649
[TBL] [Abstract][Full Text] [Related]
24. [Clinical and molecular aspects of the ACTH-independent bilateral macronodular adrenal hyperplasia].
Antonini SR; Fragoso MC; Lacroix A
Arq Bras Endocrinol Metabol; 2004 Oct; 48(5):620-36. PubMed ID: 15761531
[TBL] [Abstract][Full Text] [Related]
25. GIP-dependent adrenal Cushing's syndrome with incomplete suppression of ACTH.
Croughs RJ; Zelissen PM; van Vroonhoven TJ; Hofland LJ; N'Diaye N; Lacroix A; de Herder WW
Clin Endocrinol (Oxf); 2000 Feb; 52(2):235-40. PubMed ID: 10671952
[TBL] [Abstract][Full Text] [Related]
26. Illicit Upregulation of Serotonin Signaling Pathway in Adrenals of Patients With High Plasma or Intra-Adrenal ACTH Levels.
Le Mestre J; Duparc C; Reznik Y; Bonnet-Serrano F; Touraine P; Chabre O; Young J; Suzuki M; Sibony M; Gobet F; Stratakis CA; Raverot G; Bertherat J; Lefebvre H; Louiset E
J Clin Endocrinol Metab; 2019 Nov; 104(11):4967-4980. PubMed ID: 31074783
[TBL] [Abstract][Full Text] [Related]
27. Food-dependent Cushing's syndrome: from molecular characterization to therapeutical results.
Albiger NM; Occhi G; Mariniello B; Iacobone M; Favia G; Fassina A; Faggian D; Mantero F; Scaroni C
Eur J Endocrinol; 2007 Dec; 157(6):771-8. PubMed ID: 18057385
[TBL] [Abstract][Full Text] [Related]
28. Case of adrenocorticotropic hormone-independent macronodular adrenal hyperplasia with possible adrenal hypersensitivity to angiotensin II.
Nakamura Y; Son Y; Kohno Y; Shimono D; Kuwamura N; Koshiyama H; Sasano H; Matsuda T
Endocrine; 2001 Jun; 15(1):57-61. PubMed ID: 11572327
[TBL] [Abstract][Full Text] [Related]
29. Food-dependent Cushing's syndrome mediated by aberrant adrenal sensitivity to gastric inhibitory polypeptide.
Reznik Y; Allali-Zerah V; Chayvialle JA; Leroyer R; Leymarie P; Travert G; Lebrethon MC; Budi I; Balliere AM; Mahoudeau J
N Engl J Med; 1992 Oct; 327(14):981-6. PubMed ID: 1325609
[TBL] [Abstract][Full Text] [Related]
30. Abnormal adrenal and vascular responses to vasopressin mediated by a V1-vasopressin receptor in a patient with adrenocorticotropin-independent macronodular adrenal hyperplasia, Cushing's syndrome, and orthostatic hypotension.
Lacroix A; Tremblay J; Touyz RM; Deng LY; Lariviere R; Cusson JR; Schiffrin EL; Hamet P
J Clin Endocrinol Metab; 1997 Aug; 82(8):2414-22. PubMed ID: 9253310
[TBL] [Abstract][Full Text] [Related]
31. Intraadrenal corticotropin in bilateral macronodular adrenal hyperplasia.
Louiset E; Duparc C; Young J; Renouf S; Tetsi Nomigni M; Boutelet I; Libé R; Bram Z; Groussin L; Caron P; Tabarin A; Grunenberger F; Christin-Maitre S; Bertagna X; Kuhn JM; Anouar Y; Bertherat J; Lefebvre H
N Engl J Med; 2013 Nov; 369(22):2115-25. PubMed ID: 24283225
[TBL] [Abstract][Full Text] [Related]
32. Aberrant membrane hormone receptors in incidentally discovered bilateral macronodular adrenal hyperplasia with subclinical Cushing's syndrome.
Bourdeau I; D'Amour P; Hamet P; Boutin JM; Lacroix A
J Clin Endocrinol Metab; 2001 Nov; 86(11):5534-40. PubMed ID: 11701732
[TBL] [Abstract][Full Text] [Related]
33. Advances in the medical treatment of Cushing's syndrome.
Feelders RA; Newell-Price J; Pivonello R; Nieman LK; Hofland LJ; Lacroix A
Lancet Diabetes Endocrinol; 2019 Apr; 7(4):300-312. PubMed ID: 30033041
[TBL] [Abstract][Full Text] [Related]
34. Effect of the serotonin antagonists ritanserin and ketanserin in Cushing's disease.
Sonino N; Fava GA; Fallo F; Franceschetto A; Belluardo P; Boscaro M
Pituitary; 2000 Oct; 3(2):55-9. PubMed ID: 11141696
[TBL] [Abstract][Full Text] [Related]
35. Aberrant expression of hormone receptors in adrenal Cushing's syndrome.
Christopoulos S; Bourdeau I; Lacroix A
Pituitary; 2004; 7(4):225-35. PubMed ID: 16010457
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of hypothalamo-pituitary-adrenocortical function in children by human corticotropin-releasing hormone (MCI-028) test.
Tanaka T; Hibi I; Shimizu N; Imura H; Tanaka K; Fukata J; Fujieda K; Ichimura T; Kuribayashi T; Ito K
Endocr J; 1993 Oct; 40(5):581-9. PubMed ID: 7951524
[TBL] [Abstract][Full Text] [Related]
37. Expression of serotonin7 receptor and coupling of ectopic receptors to protein kinase A and ionic currents in adrenocorticotropin-independent macronodular adrenal hyperplasia causing Cushing's syndrome.
Louiset E; Contesse V; Groussin L; Cartier D; Duparc C; Barrande G; Bertherat J; Vaudry H; Lefebvre H
J Clin Endocrinol Metab; 2006 Nov; 91(11):4578-86. PubMed ID: 16954157
[TBL] [Abstract][Full Text] [Related]
38. Systematic analysis of G protein-coupled receptor gene expression in adrenocorticotropin-independent macronodular adrenocortical hyperplasia identifies novel targets for pharmacological control of adrenal Cushing's syndrome.
Assie G; Louiset E; Sturm N; René-Corail F; Groussin L; Bertherat J; Thomas M; Lefebvre H; Feige JJ; Clauser E; Chabre O; Cherradi N
J Clin Endocrinol Metab; 2010 Oct; 95(10):E253-62. PubMed ID: 20660048
[TBL] [Abstract][Full Text] [Related]
39. Clinical and subclinical ACTH-independent macronodular adrenal hyperplasia and aberrant hormone receptors.
Christopoulos S; Bourdeau I; Lacroix A
Horm Res; 2005; 64(3):119-31. PubMed ID: 16215323
[TBL] [Abstract][Full Text] [Related]
40. Adrenocorticotrophin-independent macronodular adrenal hyperplasia in a patient with lysine vasopressin responsiveness but insensitivity to gastric inhibitory polypeptide.
Iida K; Kaji H; Matsumoto H; Okimura Y; Abe H; Fujisawa M; Kamidono S; Chihara K
Clin Endocrinol (Oxf); 1997 Dec; 47(6):739-45. PubMed ID: 9497882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
